Skip to content

IDEAYA Biosciences, Inc. IDYA Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale

Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale at other companies

Erasca, Inc. logo
Erasca, Inc.ERAS
$58.55M+30.1%
Immunome logo
ImmunomeIMNM
$0-100%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$101.48M+46.4%
Gilead Sciences logo
Gilead SciencesGILD

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Reported directly by IDEAYA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
IDEAYA Biosciences, Inc. (IDYA) reported proceeds from maturities, prepayments and calls of debt securities, available-for-sale of $162.53M in Q1 2026.
How has IDEAYA Biosciences, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale changed year-over-year?
IDEAYA Biosciences, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale decreased by 12.8% year-over-year, from $186.35M to $162.53M.
What is the long-term trend for IDEAYA Biosciences, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
Over 4 years (2021 to 2025), IDEAYA Biosciences, Inc.'s proceeds from maturities, prepayments and calls of debt securities, available-for-sale has grown at a 29.2% compound annual growth rate (CAGR), from $243.96M to $680.23M.
What does proceeds from maturities, prepayments and calls of debt securities, available-for-sale mean?
This measures cash inflows resulting from the natural maturity or early redemption of debt securities held in the investment portfolio. It indicates the recurring cash generation from the company's fixed-income investment strategy.